CD109 and glioblastoma: CD109-silenced GSCs showed markedly reduced p-STAT3 levels compared with the nontargeted controls independently of the glioblastoma subtype (Figure 2O), thus verifying the observed association between CD109 and p-STAT3 in the patient samples.